What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction

The PARAGON-HF clinical trial suggested that sacubitril/valsartan may become a treatment option for particular subgroups of patients with heart failure and preserved ejection fraction (HFpEF). However, the proportion of real-world HFpEF patients who are theoretically superimposable with the PARAGON-...

Descripción completa

Detalles Bibliográficos
Autores principales: Rettl, René, Dachs, Theresa-Marie, Duca, Franz, Binder, Christina, Dusik, Fabian, Seirer, Benjamin, Schönauer, Johannes, Kronberger, Christina, Camuz Ligios, Luciana, Hengstenberg, Christian, Derkits, Nina, Kastner, Johannes, Badr Eslam, Roza, Bonderman, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697501/
https://www.ncbi.nlm.nih.gov/pubmed/33203151
http://dx.doi.org/10.3390/jcm9113669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697501/
https://www.ncbi.nlm.nih.gov/pubmed/33203151
http://dx.doi.org/10.3390/jcm9113669

Ejemplares similares